Nektar Therapeutics (NKTR) News

Nektar Therapeutics (NKTR): $18.81

0.01 (+0.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NKTR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

Filter NKTR News Items

NKTR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NKTR News Highlights

  • For NKTR, its 30 day story count is now at 8.
  • Over the past 10 days, the trend for NKTR's stories per day has been choppy and unclear. It has oscillated between 1 and 7.

Latest NKTR News From Around the Web

Below are the latest news stories about Nektar Therapeutics that investors may wish to consider to help them evaluate NKTR as an investment opportunity.

Leerink Partners Stick to Their Hold Rating for Nektar Therapeutics By Investing.com

Leerink Partners Stick to Their Hold Rating for Nektar Therapeutics

Investing.com | April 6, 2021

Nektar (NKTR) Down 10.9% Since Last Earnings Report: Can It Rebound?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | March 27, 2021

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.03, MarketWatch Earnings reports. Nektar Therapeutics had a negative net margin of 269.05% and a negative return on equity of 30.74%. During the same quarter in the […]

Transcript Daily | February 28, 2021

Nektar Posts Better-Than-Feared Quarterly Loss, Misses On Revenues

Nektar Therapeutics reported a better-than-expected loss in the fourth quarter but lagged analysts’ expectations for revenues. Shares of the biopharmaceutical company dropped almost 1.5% to close at $22.44 on Feb. 25. Nektar (NKTR) incurred a loss of $0.65 per share in 4Q, compared to the $0.68 loss per share estimated by analysts. Total sales generated in the quarter amounted to $23.5 million, falling short of analysts’ expectations of $30.01 million. The company’s research and development expenses were $102.7 million in the quarter, down 7% year-over-year. (See Nektar stock analysis on TipRanks) Nektar CEO Howard W.

Priti Ramgarhia on TipRanks | February 26, 2021

Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track

Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.

Yahoo | February 26, 2021

Need To Know: The Consensus Just Cut Its Nektar Therapeutics (NASDAQ:NKTR) Estimates For 2021

The analysts covering Nektar Therapeutics ( NASDAQ:NKTR ) delivered a dose of negativity to shareholders today, by...

Yahoo | February 26, 2021

Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript

Ladies and gentlemen, thank you for standing by, and welcome to the Nektar Therapeutics Fourth Quarter 2020 Financial Results. With us on the call are Howard Robin, our President and CEO; Gil Labrucherie, our COO and CFO; Dr. Jonathan Zalevsky, our Chief of Research and Development; and Dr. Brian Kotzin, our Interim Chief Medical Officer and Head of Development.

Yahoo | February 26, 2021

Nektar Therapeutics Will stock surge before Earnings results? Stock market Insights & financial analysis

Nektar Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | February 24, 2021

Mizuho Securities Stick to Their Buy Rating for Nektar Therapeutics By Investing.com

Mizuho Securities Stick to Their Buy Rating for Nektar Therapeutics

Investing.com | February 18, 2021

The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDA...

Benzinga | February 18, 2021



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7534 seconds.